A5000198776- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Esophageal and GI Pathology
- Esophageal Cancer Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Surgical Treatments
- Helicobacter pylori-related gastroenterology studies
- Colorectal and Anal Carcinomas
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
- Nutrition and Health in Aging
- Gastrointestinal disorders and treatments
- Cancer-related molecular mechanisms research
- Cancer, Lipids, and Metabolism
- Colorectal Cancer Screening and Detection
- Metabolomics and Mass Spectrometry Studies
- Enhanced Recovery After Surgery
- Surgical Simulation and Training
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Berberine and alkaloids research
- Neuroendocrine Tumor Research Advances
Institute of Science Tokyo
2025
Tokyo Medical and Dental University
2019-2024
The University of Tokyo
2024
The Japanese Society of Gastroenterological Surgery
2024
Chiba Hokusou Hospital
2024
National Cancer Center Hospital East
2017-2021
Shizuoka Cancer Center
2010-2020
Juntendo University
2019
Japanese Foundation For Cancer Research
2007-2013
The Cancer Institute Hospital
2006-2011
Importance Evidence of implementation laparoscopic gastrectomy for locally advanced gastric cancer is currently insufficient, as the primary end point in previous prospective studies was evaluated at a median follow-up time 3 years. More robust evidence necessary to verify noninferiority gastrectomy. Objective To compare 5-year survival outcomes between laparoscopy-assisted distal (LADG) and open (ODG) with D2 lymph node dissection cancer. Design, Setting, Participants This multicenter,...
10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, GC. When pertuzumab (P) was added neoadjuvant T and CT, a significant increase histopathological complete response rate observed breast cancer. This study aims investigate the benefit using both HER2 targeting drugs (T alone or combination + P), perioperative CT for localized is prospective, randomized, open-label,...
Introduction Clinical sequencing has provided molecular and therapeutic insights into the field of clinical oncology. However, despite its significance, utility in Japanese patients remains unknown. Here, we examined tissue-based with FoundationOne ® CDx Heme. Between August 2018 2019, 130 pretreated advanced solid tumors were tested or Results The median age was 60.5 years (range: 3 to 84 years), among them, 64 males 66 females. Major cancer types gastrointestinal (23 cases) hepatic,...
Laparoscopic gastrectomy (LG) is considered a standard treatment for clinical stage I gastric cancer. Nevertheless, LG has some drawbacks, such as motion restriction and difficulties in spatial perception. Robot-assisted (RG) overcomes these drawbacks by using articulated forceps, tremor-filtering capability, high-resolution three-dimensional imaging, it expected to enable more precise safer procedures than However, robust evidence based on large-scale randomized study lacking.We are...
Obesity is generally considered a risk factor for postoperative morbidity following open gastrectomy. Body mass index (BMI) widely accepted as an indicator of obesity, but does not necessarily reflect the distribution fat. It unclear how different types fat may affect operative procedure and outcome.The relationship between area (total, visceral subcutaneous fat, BMI) early surgical outcomes (bleeding, operating time, morbidity, hospital death stay) was investigated in 135 patients who had...
The incidence of adenocarcinoma the esophagogastric junction (AEG) has been increasing worldwide. We investigated clinicopathological characteristics patients with Siewert type II and III AEGs clarified optimal intra-abdominal lymph node dissection in these patients.
The clinical significance of intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity is unclear for HER2-positive gastric cancer, although it has been reported to be a significant prognosticator breast which received trastuzumab-based chemotherapy.To clarify the HER2 chemotherapy.Patients with unresectable or metastatic cancer who chemotherapy as first line treatment were included. patients classified into two groups according their status examined by immunohistochemistry...